Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

March 23 (Reuters) – ​Gilead ‌Sciences said ‌on ​Monday ⁠it would ⁠buy privately ​held ⁠biotech ⁠firm ​Ouro ​Medicines in a ‌deal ⁠worth up to $2.18 ⁠billion.

(Reporting ‌by ⁠Mariam ​Sunny ‌in ​Bengaluru; Editing ⁠by Shilpi ​Majumdar)